How Wegovy Triggers Weight Loss
Wegovy, or semaglutide, is a weekly injection that mimics GLP-1, a gut hormone released after eating. It binds to GLP-1 receptors in the brain and gut, slowing stomach emptying and signaling fullness to reduce hunger. This cuts daily calorie intake by 20-30% in trials, leading to 15% average body weight loss over 68 weeks in adults with obesity.[1][2]
Patients report eating smaller portions and fewer snacks, with effects starting within weeks as the dose ramps from 0.25 mg to 2.4 mg.
Why It Outperforms Diet Alone
Unlike calorie counting, Wegovy alters brain reward centers, curbing cravings for high-fat or sugary foods. Studies show it preserves muscle better than fasting, with fat loss concentrated in the abdomen. In the STEP trials, 83% of users lost 5% or more body weight versus 31% on placebo.[1][3]
What Happens During Treatment
- Appetite suppression: Activates hypothalamus pathways to lower ghrelin (hunger hormone).
- Delayed gastric emptying: Food stays in the stomach longer, stabilizing blood sugar.
- Improved insulin response: Boosts insulin release while reducing glucagon, aiding fat metabolism without hypoglycemia risk.
Weight plateaus after 1-2 years if doses stay maxed; maintenance requires ongoing use.[2]
Does It Work for Everyone?
Step 1 trial responders (over 5% loss at 20 weeks) hit 15.2% total loss; non-responders averaged 2.3%. Factors like starting BMI over 35 or diabetes predict better results. Kids aged 12+ saw 16% loss in a 2022 study.[3][4]
Men lose less absolute weight than women due to higher muscle mass.
Common Side Effects Tied to Weight Loss
Nausea (44% of users) and vomiting peak early, mimicking fullness and accelerating initial drops. These fade over time; diarrhea or constipation affects 20-30%. Rare pancreatitis risk (0.2%) prompts monitoring.[2][5]
How It Stacks Up Against Ozempic or Mounjaro
Wegovy uses higher-dose semaglutide than Ozempic (2.4 mg vs. 2 mg max), optimized for weight over diabetes. Mounjaro (tirzepatide) adds GIP action for 21% average loss, beating Wegovy's 15% head-to-head.[6]
| Drug | Active Ingredient | Avg. Weight Loss (68 weeks) | Weekly Dose |
|------|-------------------|-----------------------------|-------------|
| Wegovy | Semaglutide | 15% | 2.4 mg |
| Ozempic | Semaglutide | 10-12% (off-label) | Up to 2 mg |
| Mounjaro | Tirzepatide | 21% | Up to 15 mg |
When Can You Stop and Keep Weight Off?
Discontinuation rebounds 2/3 of loss within a year, per STEP 5 extension. Pairing with diet/exercise sustains 10% loss longer.[1]
Sources
[1]: NEJM STEP 1 Trial
[2]: Novo Nordisk Wegovy Prescribing Info
[3]: NEJM STEP 8 Trial
[4]: Novo Nordisk Adolescent Study
[5]: FDA Wegovy Label
[6]: NEJM SURMOUNT-1 Trial